Evaluation of endometrial changes and p53 expression in tamoxifen treated women: comparison of various methods.
暂无分享,去创建一个
[1] M. Gonen,et al. Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. , 2004, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[2] P. Aldhous. Stem cells: Panacea, or Pandora's box? , 2000, Nature.
[3] G. Bertelli,et al. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. , 2000, Gynecologic oncology.
[4] F. Penault-Llorca,et al. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. , 2000, Gynecologic oncology.
[5] T. Soussi,et al. p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.
[6] M. Sherman. Theories of Endometrial Carcinogenesis: A Multidisciplinary Approach , 2000, Modern Pathology.
[7] L. Mariani,et al. Serum evaluation of P53 protein in patients with gynaecological cancer. , 2000, Anticancer research.
[8] B. Elhelw,et al. Saline sonohysterography for monitoring asymptomatic postmenopausal breast cancer patients taking tamoxifen , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[9] B. Muir,et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Flex,et al. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. , 1999, Journal of clinical pathology.
[11] A. V. D. Van Der Zee,et al. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. , 1999, Gynecologic oncology.
[12] I. Cohen,et al. The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment. , 1998, Obstetrical & gynecological survey.
[13] T. Bourne,et al. A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. , 1998, American journal of obstetrics and gynecology.
[14] T. Kasamatsu,et al. Random Nuclear p53 Overexpression Pattern In Tamoxifen‐Mediated Endometrial Carcinoma , 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[15] P. Buytaert. Tamoxifen: panacea or Pandora??s box? , 1998 .
[16] P. Neven,et al. Longitudinal hysteroscopic follow-up during tamoxifen treatment , 1998, The Lancet.
[17] K. Hemminki,et al. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. , 1996, Cancer research.
[18] F. Demirkıran,et al. Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen. , 1996, European journal of obstetrics, gynecology, and reproductive biology.
[19] A. Figer,et al. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[20] B. Karlan,et al. HER‐2/neu, p53, and DNA Analyses as Prognosticators for Survival in Endometrial Carcinoma , 1995, Obstetrics and gynecology.
[21] I. Cohen,et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. , 1994, Gynecologic oncology.
[22] T. Bourne,et al. Effects of tamoxifen on uterus , 1994, The Lancet.
[23] A. Kauppila,et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. , 1993, Obstetrics and gynecology.
[24] Nils Wilking,et al. ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS , 1989, The Lancet.
[25] I. Zusman,et al. Serological and immunohistochemical determinations of p53 protein in diagnosis of endometrial cancer: a comparative study. , 1997, European journal of gynaecological oncology.